Group 1 - The company Jinshi Technology announced an incentive plan involving 31 individuals, with a total of approximately 3.87 million restricted shares to be granted, representing 0.96% of the company's total share capital of 405 million shares at the time of the announcement [1] - The grant price for the restricted shares is set at 7.71 yuan per share, with a maximum validity period of 48 months from the completion of the registration of the restricted shares [1] - As of the report date, Jinshi Technology's market capitalization is 6.3 billion yuan [1] Group 2 - For the first half of 2025, the company's revenue is entirely derived from its energy storage business, accounting for 100% of its revenue [1]

Core Viewpoint - Guangdong Yidoli Biotechnology Co., Ltd. held an online investor meeting to discuss its mid-year performance and future strategies, focusing on product development and market expansion [1][2]. Group 1: Investor Relations Activity - The investor meeting took place on September 19, 2025, from 15:30 to 17:00 on the "Panorama Roadshow" website [2]. - Key personnel present included CEO Zhou Derong, independent director Yuan Ziqiang, CFO Huang Xiaoping, and board secretary Zhu Shanmin [2]. Group 2: Product Development and Market Strategy - The company has ceased production of Vitamin B12 due to market conditions and has made progress in animal plant extracts, completing various trials and obtaining new product certificates for red clover and stone mint extracts [2]. - In the human plant extract segment, the company developed multiple new products and optimized extraction processes, aiming for significant sales growth in overseas markets, with preparations for its German subsidiary completed [2]. Group 3: Production Capacity and Marketing - In 2024, the company produced 41,533 tons of biological enzyme preparations and sold 42,383 tons, achieving near full capacity utilization [2]. - The company is investing in new and upgraded projects across four bases to increase production capacity, while also expanding its global market presence by registering products in over 30 countries and establishing long-term partnerships with more than 2,300 quality clients [2]. Group 4: Shareholder Information and Market Management - As of September 10, 2025, the company had 20,222 shareholders [2]. - The management is focusing on core business development, research innovation, global market expansion, and efficiency improvements to achieve performance growth and high-quality development, alongside cash dividends, share buybacks, and equity incentives for market value management [2].

Production and Market Strategy - The company has halted the production of Vitamin B12 due to market reasons [2] - In 2024, the production of biological enzyme preparations reached 41,533 tons, with sales of 42,383 tons, indicating a near-saturation capacity utilization [2] - The company is focusing on expanding its global market presence, having registered products in over 30 countries and established long-term partnerships with over 2,300 clients [2] Research and Development - The company has made progress in developing new products, including plant extracts and fermentation products, while optimizing extraction processes for various plants [2] - New product certifications have been obtained for feed and feed additives, enhancing the company's product portfolio [2] Financial Performance and Shareholder Engagement - As of September 10, 2025, the number of shareholders is 20,222 [4] - The management is committed to improving company performance and achieving the goals set in the equity incentive plan over the next three years [5] - The company is actively engaging in value management through cash dividends, share buybacks, and equity incentives [6] Market Position and Challenges - The company is addressing the challenge of its stock price being close to net asset value, which is uncommon for growth stocks [5] - The management emphasizes the importance of maintaining a strong domestic market position while pursuing international expansion [5]

Group 1 - The company held its 26th meeting of the fifth board of directors on September 19, 2025, to discuss various resolutions [1][2][4] - The board approved the first phase of the 2024 restricted stock incentive plan, allowing 8 eligible participants to unlock a total of 234,080 shares, representing approximately 0.0996% of the company's total share capital [2][26][30] - The board also approved the repurchase and cancellation of 48,720 shares of restricted stock from 3 participants who have left the company, at a repurchase price of 7.6786 yuan per share [5][41][48] Group 2 - The company decided to postpone the shareholders' meeting until further notice, pending the completion of related work and preparations [9][58] - The board's resolutions were based on prior approvals from the remuneration and assessment committee, ensuring compliance with relevant laws and regulations [4][7][35] - The company will proceed with the necessary procedures for the unlocking of shares and the repurchase of restricted stocks as per the established regulations [36][55]

Core Viewpoint - Dalian Shengya Tourism Holdings Co., Ltd. has approved the "2025 Restricted Stock Incentive Plan (Draft)" and its summary during the board and supervisory meetings held on July 26, 2025, and has publicly disclosed the list of initial incentive recipients [1][7]. Disclosure Situation - The company published the list of initial incentive recipients on August 19, 2025, through internal bulletin boards and the OA system, with the public disclosure period lasting until August 28, 2025 [1][7]. Verification Situation - The supervisory board verified the list of initial incentive recipients, including their identification documents, employment contracts with the company and its subsidiaries, and their positions within the company [3][9]. Verification Opinions - The supervisory board confirmed that the individuals listed as initial incentive recipients meet the qualifications and conditions set forth in relevant laws and regulations, including the Company Law and the Securities Law [4][10]. - None of the initial incentive recipients fall under the disqualifications outlined in Article 8 of the Management Measures, such as being deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [5][11]. - The initial incentive recipients are all directors, senior management, middle management, and key employees of the company and its subsidiaries, excluding independent directors, supervisors, and shareholders holding more than 5% of the company's shares [6][12]. - The basic information regarding the initial incentive recipients is accurate, with no falsehoods or significant omissions [6][12].

Core Viewpoint - Anqihome Co., Ltd. is repurchasing and canceling a portion of its restricted stock due to the departure and job transfers of certain incentive recipients [1][2]. Group 1: Repurchase and Cancellation Details - The company held its 10th Board of Directors' fourth meeting on July 24, 2025, where it approved the repurchase and cancellation of 80,000 shares of restricted stock from four incentive recipients who no longer meet the incentive conditions [2]. - The repurchase is based on the company's 2024 Restricted Stock Incentive Plan and follows the relevant regulations [2]. - After the cancellation, the remaining restricted stock will total 10,908,000 shares [2]. Group 2: Legal and Compliance Aspects - A legal opinion was issued confirming that the repurchase and cancellation have obtained necessary approvals and have fulfilled information disclosure obligations [3]. - The public notice period for creditors has been completed without any claims for debt repayment or guarantees [2][3]. - The company is required to complete subsequent legal procedures and continue fulfilling its information disclosure obligations [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600526 证券简称：菲达环保 公告编号：临2025-044 浙江菲达环保科技股份有限公司 股权激励限制性股票回购注销实施公告 一、本次限制性股票回购注销的决策与信息披露 2025年7月21日，公司第九届董事会第十四次会议和第九届监事会第十一次会议审议通过了《关于回购 注销2023年限制性股票激励计划中部分激励对象已获授但尚未解除限售的限制性股票的议案》。具体内 容详见公司于2025年7月22日在上海证券交易所网站（www.sse.com.cn）和指定信息披露媒体披露的 《浙江菲达环保科技股份有限公司关于回购注销部分限制性股票及调整回购价格的公告》（公告编号： 临2025-034）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购注销原因 1、发生异动情形。浙江菲达环保科技股份有限公司（以下简称公司或菲达环保）2023年限制性股票激 励计划首次授予的7名激励对象因岗位调动或已离职不再具备激励对象资格，根据公司《2023年限制性 股票激励计划 ...

Core Points - The company approved the 2024 restricted stock incentive plan, granting 1.44 million shares to 47 eligible participants at a price of RMB 6.86 per share on August 5, 2025 [2][4] - The total funds raised from this incentive plan amount to RMB 9,878,400, which will be used to supplement the company's working capital [6][8] - The effective period of the incentive plan is up to 48 months, with a lock-up period for the granted shares [3][5] Summary by Sections Granting Details - The actual number of restricted shares granted is 1.44 million, with 47 participants involved [4] - The shares were sourced from the company's repurchase of its own A-shares in the secondary market [6] Lock-up and Release Conditions - The lock-up period for the granted shares varies, with specific durations of 12, 24, and 36 months [5] - Shares cannot be transferred or used as collateral until the lock-up conditions are met [5] Financial Impact - The total expense to be recognized for the 1.44 million shares is estimated at RMB 17.38 million, to be amortized over the lock-up period [7] - The incentive plan is expected to positively influence the company's performance, outweighing the costs associated with the plan [7]

Core Viewpoint - The announcement details the approval and implementation of the 2025 Stock Option Incentive Plan by the company, including the number of options granted, the conditions for granting, and the adjustments made to the plan due to changes in the list of eligible participants [2][31]. Summary by Sections Incentive Plan Overview - The 2025 Stock Option Incentive Plan was approved during the company's board meetings held on September 18, 2025, with a total of 15.125 million stock options granted to 621 participants [2][6][31]. - The exercise price for the stock options is set at 37.98 yuan per share [3][16]. Approval Process - The plan underwent several approval steps, including meetings on August 21, September 3, and September 9, 2025, where various related proposals were discussed and approved [9][10][11][32]. - The company conducted a public notice period from August 23 to September 1, 2025, during which no objections were raised regarding the list of incentive participants [10][32]. Adjustments to the Plan - The number of participants was adjusted from 624 to 621, and the total number of stock options granted was reduced from 15.159 million to 15.125 million due to some participants opting out [31][34]. - The adjustments were within the authorized scope and did not require further shareholder approval [34]. Granting Conditions - The granting of stock options is contingent upon the company meeting specific performance criteria over the fiscal years 2025 to 2027, with annual assessments of net profit [7][12]. - Individual performance assessments will also determine the actual number of options that can be exercised by each participant [8][12]. Financial Impact - The funds raised through this incentive plan will be used to supplement the company's working capital [21]. - The company anticipates that the incentive plan will positively influence its financial performance, outweighing the costs associated with the stock options [24][47]. Legal and Advisory Opinions - Legal opinions confirm that the adjustments and the granting of stock options comply with relevant laws and regulations [27][36]. - An independent financial advisor has also validated that the conditions for granting the stock options have been met [38].

拨康视云-B(02592)发布公告，于2025年9月18日，根据首次公开发售后股权激励计划向四名雇员参与者 授出428.42万份受限制股份单位，但须获承授人接纳，方可作实。 ...